Compare Bristol-Myers Squibb Co (BMY) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sunrun Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.49 (market cap $116.30B), while Sunrun Inc trades at $12.54 (market cap $3.05B). The key difference: Bristol-Myers Squibb Co is far larger — about 38.1× Sunrun Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| BMY | RUN | |
|---|---|---|
Market Cap | $116.30B | $3.05B |
Sector | Health | Technology |
52-Week High | $62.37 | $21.41 |
52-Week Low | $42.60 | $9.07 |
Enterprise Value | $152.24B | $17.24B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Sunrun (RUN) trades at $12.41, down 0.48% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 17.88% net income margin and ROE of 19.06%, while valuation metrics like P/E of 6 and P/B of 0.91 suggest potential undervaluation. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, driving investor interest in grid-support initiatives tied to AI data center demand.
The stock presents a mixed outlook: analyst consensus is strongly bullish with a $17.09 price target (62% buy ratings), but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Growth catalysts include expanding revenue and margin trends, though execution on new ventures and macroeconomic pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
